Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates

Authors

  • Mirjana Lulic-Botica BSc, RPh, BCPS,

    1. Department of Pharmacy, Hutzel Women's Hospital, Detroit, MI, USA
    2. Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
    Search for more papers by this author
  • Terri Sheer PharmD,

    1. Department of Pharmacy, Hutzel Women's Hospital, Detroit, MI, USA
    Search for more papers by this author
  • David Edwards BScPhm, PharmD, MPH,

    1. Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
    Search for more papers by this author
  • Ronald L. Thomas PhD,

    1. Division of Biostatistics, Children's Hospital of Michigan, Detroit, MI, USA
    Search for more papers by this author
  • Girija Natarajan MD

    Corresponding author
    1. Division of Neonatology, Children's Hospital of Michigan, Wayne State University, Detroit, MI, USA
    • Corresponding Author: Girija Natarajan, MD, Division of Neonatal–Perinatal Medicine, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI, USA

      Email: gnatara@med.wayne.edu

    Search for more papers by this author

Abstract

We compared gentamicin pharmacokinetics among neonates born small-for-gestational age (SGA) and appropriate for gestational age (AGA). We further compared gentamicin pharmacokinetics in subgroups of AGA and SGA neonates born preterm and term and treated within and after the initial week of age. Steady state peak and trough serum gentamicin concentrations were used to calculate clearance (Cl), elimination constant (Kel), volume of distribution (Vd), and half-life (t1/2) in infants (n = 236) who received ≥48 hours therapy. Statistical analyses (SPSS 17.0) included chi-square and the non-parametric Mann–Whitney U-test. SGA infants treated early (≤7days) (n = 29) and at postmenstrual ages ≤32 weeks (n = 23) had significantly lower median Kel (0.069/h vs. 0.081/h and 0.067/h vs. 0.075/h) and clearance (0.58 mL/kg/min vs. 0.68 mL/kg/min and 0.46 mL/kg/min vs. 0.65 mL/kg/min), compared to those born AGA. There were no significant differences in pharmacokinetic profiles with later therapy or at more mature ages. The prolonged half-life of gentamicin may need to be considered in dosing regimens for preterm SGA infants in the initial week of life.

Ancillary